Dr. Reddy's Laboratories Ltd.
) recently announced the launch of its therapeutic equivalent
generic version of
) Lamictal XR (lamotrigine) extended-release tablets (25 mg,
50 mg, 100 mg, 200 mg, 300 mg) in the US.
The launch followed the approval by the US Food and Drug
Administration (FDA) of Abbreviated New Drug Application (ANDA)
submitted by the company for Lamictal XR.
Lamictal XR is used in combination with other therapies for
treating primary generalized tonic-clonic seizures and partial
onset seizures in patients with a minimum age of 13
years.According to IMS Health, Lamictal XR (branded and generic
version both) generated US revenues of approximately $300.5
million MAT (moving annual total) for the last 12 months ending
Dr. Reddy's boasts of a strong generic product portfolio.
Revenues at the Global Generics segment were up 17.5% to $1.5
billion for the fiscal year 2013 (ended Mar 31).
Strong sales in North America and emerging markets were
primarily responsible for the growth displayed by the Global
Generics division. Generics revenue increased in North America
(up 19%), Russia (up 27%), other CIS (Commonwealth of Independent
States) markets (up 28%), India (up 13%) and the rest of the
world/RoW (up 42%).
In Jan 2013, Wockhardt Ltd., an Indian company, launched the
generic version of Lamictal XR in the US in 25mg, 50mg,
100mg, 200mg and 300mg extended release tablets.
Dr. Reddy's carries a Zacks Rank #3 (Hold) while
GlaxoSmithKline carries a Zacks Rank #4 (Sell). Currently,
Salix Pharmaceuticals Ltd.
) look more attractive in the pharma space with a Zacks Rank #1
GLAXOSMITHKLINE (GSK): Free Stock Analysis
DOCTOR REDDYS (RDY): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.